Najat Khan
CEO and President, Director · RECURSION PHARMACEUTICALS, INC.
- 2025
- Sep 10, 2026
- 10
Summary
Latest filing:
Najat Khan is CEO and President, Director of RECURSION PHARMACEUTICALS, INC. (RXRX). 10 SEC Form 4 filings on record going back to 2025, most recently on 10 September 2026. Most recent open-market trade: sold $79K of RXRX on 10 September 2026. Lifetime open-market sales: $460K.
Recent transactions
13The latest 13 SEC Form 4 transactions reported by Najat Khan.
Trading pattern
InsiderAlpha's records for Najat Khan go back to 2025: 10 primary Form 4 filings, an average of 5.0 per year. 3 recorded transactions carry a Rule 10b5-1 plan flag. This identifies the marked transactions as reported under a trading plan; it does not establish the plan status of unmarked transactions.
Other insiders active in the same stocks
Insiders who reported open-market trades in the last 12 months at the companies Najat Khan files at. Multiple unrelated insiders buying the same stock within a short window, cluster buying, has historically been one of the strongest Form 4 signals.
- Blake Borgeson - $3.38M in RXRX purchases and sales in the last 12 months
- Christopher Gibson - $2.41M in RXRX purchases and sales in the last 12 months
- Robert Hershberg - $125K in RXRX purchases and sales in the last 12 months
- Ben R. Taylor - $68K in RXRX purchases and sales in the last 12 months
- Namandje Bumpus - $28K in RXRX purchases and sales in the last 12 months
More insiders (A-Z)
Browse nearby insider profiles in alphabetical order.
Frequently asked questions
Who is Najat Khan?
Najat Khan is a corporate insider, tracked as CEO and President, Director of RECURSION PHARMACEUTICALS, INC. (RXRX). InsiderAlpha holds 10 primary Form 4 filings for them, the earliest from 2025, updated as new SEC EDGAR filings are processed.
How many SEC Form 4 filings has Najat Khan submitted recently?
2 primary Form 4 filings in the last 90 days, covering 1 company.
Has Najat Khan been buying or selling stock?
Recorded transactions: 0 open-market purchases and 4 open-market sales ($460K) across all tracked filings.